There was no significant association between anti-TNF therapy and the risk of solid malignancies (OR 1.2, 95% CI 0.91–1.6) or hematologic malignancies (OR 0.57, 95% CI 0.25–1.3). This evidence concerns the gene TNF and hematologic disorder.